A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

Prior treatment

• Current drug-induced psoriasis

Other illness

• Current diagnosis, signs, or symptoms of severe, progressive, or uncontrolled disease involving the renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic systems
• Known allergy, hypersensitivity, or intolerance to HSK47388。
• A history of malignant tumor before screening;

Other

• Non-plaque psoriasis (e.g., erythrodermic, guttate, or pustular psoriasis)
• Subjects deemed unsuitable for participation due to other factors as determined by the investigator

• Confirmed diagnosis of plaque psoriasis with a disease duration of at least 26 weeks before the first administration of the study intervention
• Total Body Surface Area (BSA) involvement ≥ 10% at both screening and baseline visits
• Psoriasis Area and Severity Index (PASI) total score ≥ 12 at both screening and baseline visits
• Investigator Global Assessment (IGA) for plaque psoriasis total score ≥ 3 (moderate or severe disease) at both screening and baseline visits
• Participants deemed appropriate candidates for systemic therapy for plaque psoriasis